Article in Chemical science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors.
Bolin ChenState Key Laboratory of Medicinal Chemical Biology, Frontiers Science Center for New Organic Matter, Nankai University 94 Weijin Road Tianjin 300071 China 017095@nankai.edu.cn lwang@nankai.edu.cn yuechen@nankai.edu.cn.
Xijing ZhangState Key Laboratory of Medicinal Chemical Biology, Frontiers Science Center for New Organic Matter, Nankai University 94 Weijin Road Tianjin 300071 China 017095@nankai.edu.cn lwang@nankai.edu.cn yuechen@nankai.edu.cn.
Yufen YangCollege of Pharmacy, Nankai University 38 Tongyan Road Tianjin 300353 China.
Dongdong XuCollege of Pharmacy, Nankai University 38 Tongyan Road Tianjin 300353 China.
Qianwei WuCollege of Pharmacy, Nankai University 38 Tongyan Road Tianjin 300353 China.
Shibo WangState Key Laboratory of Medicinal Chemical Biology, Frontiers Science Center for New Organic Matter, Nankai University 94 Weijin Road Tianjin 300071 China 017095@nankai.edu.cn lwang@nankai.edu.cn yuechen@nankai.edu.cn.
Shiqi BaoAccendatech Co. Ltd 32nd Floor, Rongqiao Center, Intersection of Changjiang Road and Nankai Six Road Tianjin 300102 China.
Xuemei ZhangAccendatech Co. Ltd 32nd Floor, Rongqiao Center, Intersection of Changjiang Road and Nankai Six Road Tianjin 300102 China.
Yahui DingState Key Laboratory of Medicinal Chemical Biology, Frontiers Science Center for New Organic Matter, Nankai University 94 Weijin Road Tianjin 300071 China 017095@nankai.edu.cn lwang@nankai.edu.cn yuechen@nankai.edu.cn.
Liang WangState Key Laboratory of Medicinal Chemical Biology, Frontiers Science Center for New Organic Matter, Nankai University 94 Weijin Road Tianjin 300071 China 017095@nankai.edu.cn lwang@nankai.edu.cn yuechen@nankai.edu.cn.ORCID https://orcid.org/0000-0001-9132-6222
Yue ChenState Key Laboratory of Medicinal Chemical Biology, Frontiers Science Center for New Organic Matter, Nankai University 94 Weijin Road Tianjin 300071 China 017095@nankai.edu.cn lwang@nankai.edu.cn yuechen@nankai.edu.cn.ORCID https://orcid.org/0000-0002-1317-7097
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
A concise and collective synthetic route to hypocretenolides was developed for the first time. This route features one-pot addition-alkylation and intramolecular 1,3-dipolar cycloaddition to efficiently assemble the 5/7/6 ring system. Our syntheses enabled multigram preparation of hypocretenolide which facilitated further biological evaluation. Preliminary CCK-8 cytotoxic results of hypocretenolide indicated its IC
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Hypocretenolides: collective total syntheses and activities toward metastatic colon cancer. · full record | OpenQuestion